Challenges and Considerations of Preclinical Development for iPSC-Based Myogenic Cell Therapy

Area of Science:

• Regenerative Medicine
• Stem Cell Therapy
• Musculoskeletal Biology

Background:

• Induced pluripotent stem cells (iPSCs) offer immune-compatible, expandable cell sources for regenerative medicine.
• Skeletal muscle's syncytial nature supports stem cell integration, making it amenable to gene editing for myopathies.
• iPSC-based therapies are being explored for muscular dystrophies and tissue regeneration.

Purpose of the Study:

• To review the preclinical development of iPSC-derived myogenic cell transplantation therapies.
• To discuss challenges and potential solutions for clinical translation of these therapies.
• To describe preclinical models for evaluating iPSC-derived myogenic cells.

Main Methods:

• Overview of iPSC differentiation and lineage specification for myogenic cells.
• Analysis of scaling-up, delivery, and cGMP compliance processes.
• Review of preclinical models for assessing cell therapy efficacy and safety.

Main Results:

• Preclinical studies demonstrate the potential of iPSC-derived myogenic cells for muscle regeneration.
• Challenges include in vivo differentiation uncertainty, potential tumorigenicity, and epigenetic abnormalities.
• Successful clinical translation remains limited despite promising preclinical data.

Conclusions:

• iPSC-derived myogenic cell therapies hold significant potential for treating muscle diseases.
• Addressing safety, manufacturing, and regulatory hurdles is crucial for clinical application.
• Further development of preclinical models is needed to support therapeutic advancements.